PL2655604T3 - Szczepionki adenowirusowe serotyp 26 i serotyp 35 przeciwko filowirusom - Google Patents
Szczepionki adenowirusowe serotyp 26 i serotyp 35 przeciwko filowirusomInfo
- Publication number
- PL2655604T3 PL2655604T3 PL11849865T PL11849865T PL2655604T3 PL 2655604 T3 PL2655604 T3 PL 2655604T3 PL 11849865 T PL11849865 T PL 11849865T PL 11849865 T PL11849865 T PL 11849865T PL 2655604 T3 PL2655604 T3 PL 2655604T3
- Authority
- PL
- Poland
- Prior art keywords
- serotype
- adenovirus
- filovirus vaccines
- filovirus
- vaccines
- Prior art date
Links
- 241000711950 Filoviridae Species 0.000 title 1
- 241000205701 Human adenovirus 26 Species 0.000 title 1
- 241000701124 Human adenovirus 35 Species 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
- C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42295410P | 2010-12-14 | 2010-12-14 | |
| PCT/US2011/064944 WO2012082918A1 (en) | 2010-12-14 | 2011-12-14 | Adenovirus serotype 26 and serotype 35 filovirus vaccines |
| EP11849865.8A EP2655604B1 (en) | 2010-12-14 | 2011-12-14 | Adenovirus serotype 26 and serotype 35 filovirus vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2655604T3 true PL2655604T3 (pl) | 2019-02-28 |
Family
ID=46245095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11849865T PL2655604T3 (pl) | 2010-12-14 | 2011-12-14 | Szczepionki adenowirusowe serotyp 26 i serotyp 35 przeciwko filowirusom |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9701718B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2655604B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6054876B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101879892B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN103370411B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2011343798B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112013014712B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2821289C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2655604T3 (cg-RX-API-DMAC7.html) |
| EA (1) | EA029504B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2676196T3 (cg-RX-API-DMAC7.html) |
| PL (1) | PL2655604T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012082918A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201304260B (cg-RX-API-DMAC7.html) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013014712B1 (pt) | 2010-12-14 | 2021-03-02 | The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | primeiro e segundo vetores de adenovírus recombinantes |
| ZA201608812B (en) | 2014-06-26 | 2019-08-28 | Janssen Vaccines & Prevention Bv | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
| AU2015279089B2 (en) | 2014-06-26 | 2021-01-28 | Janssen Vaccines & Prevention B.V. | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
| CA2960092C (en) * | 2014-09-03 | 2021-05-04 | Bavarian Nordic A/S | Vaccine combination including vectors comprising nucleic acid encoding antigens from filovirus subtypes |
| KR20190062617A (ko) | 2014-09-03 | 2019-06-05 | 버베리안 노딕 에이/에스 | 면역 반응을 증대시키기 위한 방법 및 조성물 |
| LT3197489T (lt) | 2014-09-26 | 2021-07-26 | Beth Israel Deaconess Medical Center, Inc. | Būdai ir kompozicijos, skirti indukuoti apsauginį imunitetą prieš žmogaus imunodeficito viruso infekciją |
| WO2016146844A1 (en) | 2015-03-18 | 2016-09-22 | Janssen Vaccines & Prevention B.V. | Assays for recombinant expression systems |
| RS62360B1 (sr) | 2015-12-15 | 2021-10-29 | Janssen Vaccines & Prevention Bv | Antigeni, vektori i sastavi virusa humane imunodeficijencije, i postupci njihove primene |
| MX2018009997A (es) | 2016-02-18 | 2019-02-07 | Int Flavors & Fragrances Inc | Composiciones de cápsulas de poliurea. |
| CN109070038B (zh) | 2016-03-18 | 2021-08-31 | 国际香料和香精公司 | 二氧化硅微胶囊及其制备方法 |
| EP3471765B1 (en) | 2016-06-16 | 2024-04-24 | Janssen Vaccines & Prevention B.V. | Hiv vaccine formulation |
| BR112018076803B1 (pt) | 2016-07-01 | 2022-05-03 | International Flavors & Fragrances Inc | Composição estável de microcápsula, e, produto de consumo |
| US10925955B2 (en) | 2016-07-15 | 2021-02-23 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against a Marburg virus infection |
| EP3484507A1 (en) | 2016-07-15 | 2019-05-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against a marburg virus infection |
| EP3512625B1 (en) | 2016-09-16 | 2023-04-26 | International Flavors & Fragrances Inc. | Microcapsule compositions stabilized with viscosity control agents |
| US20180085291A1 (en) | 2016-09-28 | 2018-03-29 | International Flavors & Fragrances Inc. | Microcapsule compositions containing amino silicone |
| US11173204B2 (en) | 2017-04-06 | 2021-11-16 | Janssen Vaccines & Prevention B.V. | MVA-BN and Ad26.ZEBOV or Ad26.filo prime-boost regimen |
| US20180346648A1 (en) | 2017-05-30 | 2018-12-06 | International Flavors & Fragrances Inc. | Branched polyethyleneimine microcapsules |
| ES2976495T3 (es) | 2017-06-15 | 2024-08-02 | Janssen Vaccines & Prevention Bv | Vectores poxvirus que codifican antígenos del VIH y métodos de uso de los mismos |
| WO2019018724A1 (en) | 2017-07-21 | 2019-01-24 | Janssen Vaccines & Prevention B.V. | METHODS FOR SAFE INDUCTION OF MULTICLADED CROSS-IMMUNITY AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN HUMAN BEINGS |
| CN111163799A (zh) | 2017-07-28 | 2020-05-15 | 扬森疫苗与预防公司 | 用于异源repRNA免疫接种的方法和组合物 |
| BR112020007884A2 (pt) | 2017-11-20 | 2020-11-03 | Janssen Pharmaceuticals, Inc. | método de proporcionar uma administração segura de vetores adenovirais que codificam um antígeno de vírus zika |
| MX2020006471A (es) | 2017-12-19 | 2020-09-22 | Janssen Sciences Ireland Unlimited Co | Metodos y composiciones para inducir una respuesta inmune contra el virus de hepatitis b (hbv). |
| MX2020011366A (es) | 2018-04-27 | 2020-11-24 | Int Flavors & Fragrances Inc | Composiciones estables de microcapsulas de poliurea. |
| WO2020016394A1 (en) | 2018-07-20 | 2020-01-23 | Janssen Vaccines & Prevention B.V. | Recombinant adenoviral vector expressing zika antigen with improved productivity |
| AU2019345942A1 (en) | 2018-09-25 | 2021-03-18 | Janssen Vaccines & Prevention B.V. | Method of inducing an immune response against human immunodeficiency virus by co-localized administration of vaccine components |
| US12303856B2 (en) | 2018-12-18 | 2025-05-20 | International Flavors & Fragrances Inc. | Hydroxyethyl cellulose microcapsules |
| PH12021552797A1 (en) | 2019-05-14 | 2022-09-19 | Janssen Biotech Inc | Ultrafiltration/diafiltration (uf/df) process |
| JP2023512519A (ja) | 2020-01-31 | 2023-03-27 | ベス イスラエル ディーコネス メディカル センター インコーポレイテッド | コロナウイルス感染症を予防および処置するための組成物および方法－ｓａｒｓ－ｃｏｖ－２ワクチン |
| WO2021228842A1 (en) | 2020-05-11 | 2021-11-18 | Janssen Pharmaceuticals, Inc. | Stabilized coronavirus spike protein fusion proteins |
| IL299515A (en) | 2020-06-29 | 2023-02-01 | Janssen Vaccines & Prevention Bv | Vaccine combination against respiratory syncytial virus infection |
| WO2022008438A1 (en) | 2020-07-06 | 2022-01-13 | Janssen Pharmaceuticals, Inc. | Stabilized corona virus spike protein fusion proteins |
| WO2022008613A1 (en) | 2020-07-08 | 2022-01-13 | Janssen Sciences Ireland Unlimited Company | Rna replicon vaccines against hbv |
| MX2022002609A (es) * | 2020-08-22 | 2022-06-08 | Federal State Budgetary Institution National Res Centre For Epidemiology And Microbiology Named Afte | Vector de expresion para el desarrollo de un agente inmunobiologico para inducir inmunidad especifica contra el virus de sindrome respiratorio agudo grave sars-cov-2 (variantes). |
| WO2022175479A1 (en) | 2021-02-19 | 2022-08-25 | Janssen Vaccines & Prevention B.V. | Vaccine combinations against respiratory syncytial virus strain a and b infections |
| AU2022221983A1 (en) | 2021-02-19 | 2023-08-17 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv fb antigens |
| EP4314019A2 (en) | 2021-04-01 | 2024-02-07 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion piv3 f proteins |
| EP4124383A1 (en) | 2021-07-27 | 2023-02-01 | International Flavors & Fragrances Inc. | Biodegradable microcapsules |
| WO2023020939A1 (en) | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| WO2023026182A1 (en) | 2021-08-24 | 2023-03-02 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| EP4154974A1 (en) | 2021-09-23 | 2023-03-29 | International Flavors & Fragrances Inc. | Biodegradable microcapsules |
| WO2023047348A1 (en) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceuticals, Inc. | Stabilized corona virus spike protein fusion proteins |
| WO2023047349A1 (en) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceuticals, Inc. | Stabilized coronavirus spike protein fusion proteins |
| WO2023111725A1 (en) | 2021-12-14 | 2023-06-22 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| EP4448802A1 (en) | 2021-12-16 | 2024-10-23 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion hmpv fusion proteins |
| WO2023198815A1 (en) | 2022-04-14 | 2023-10-19 | Janssen Vaccines & Prevention B.V. | Sequential administration of adenoviruses |
| EP4590690A1 (en) | 2022-09-23 | 2025-07-30 | Janssen Vaccines & Prevention B.V. | Pre-fusion human piv1 f proteins |
| EP4590689A1 (en) | 2022-09-23 | 2025-07-30 | Janssen Vaccines & Prevention B.V. | Stabilized trimeric class i fusion proteins |
| WO2024061759A1 (en) | 2022-09-23 | 2024-03-28 | Janssen Vaccines & Prevention B.V. | Stabilized coronavirus s proteins |
| AU2023355822A1 (en) | 2022-10-06 | 2025-04-17 | Msd International Business Gmbh | Stabilized pre-fusion piv3 f proteins |
| EP4406641A1 (en) | 2023-01-26 | 2024-07-31 | International Flavors & Fragrances Inc. | Biodegradable microcapsules containing low log p fragrance |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6852324B1 (en) * | 1997-12-23 | 2005-02-08 | The United States Of America As Represented By The Department Of Health And Human Services | Immunization for ebola virus infection |
| US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| ES2307093T3 (es) * | 2001-10-01 | 2008-11-16 | THE GOVERNMENT OF THE USA, AS REPR. BY SECRETARY, DEPT. HEALTH & HUMAN SERVICES, NAT. INST OF HEALTH | Desarrollo de un vacuna preventiva para la infeccion por filovirus en primates. |
| WO2004001032A2 (en) | 2002-04-25 | 2003-12-31 | Crucell Holland B.V. | Stable adenoviral vectors and methods for propagation thereof |
| BR0308783A (pt) | 2002-04-25 | 2005-01-04 | Crucell Holland Bv | Vetor de adenovìrus recombinante, método para produzir um vetor de adenovìrus recombinante, composição farmacêutica, método para tratar um corpo humano, e, kit de partes |
| AU2003288273A1 (en) * | 2002-10-23 | 2004-05-13 | Crucell Holland B.V. | New settings for recombinant adenoviral-based vaccines |
| WO2005012538A2 (en) * | 2003-08-01 | 2005-02-10 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Accelerated vaccination |
| CA2581840C (en) | 2004-09-27 | 2014-08-05 | Crucell Holland B.V. | Optimized vaccines to provide protection against ebola and other viruses |
| JP4843613B2 (ja) * | 2004-10-13 | 2011-12-21 | クルセル ホランド ベー ヴェー | 改良されたアデノウイルスベクターおよびその使用方法 |
| BRPI0516048A (pt) | 2004-10-13 | 2008-08-19 | Crucell Holland B V E Beth Isr | batelada de um adenovìrus recombinante defectivo em replicação baseado em um sorotipo do subgrupo c |
| MX2007004031A (es) * | 2004-10-14 | 2007-11-08 | Crucell Holland Bv | Vacunas de cebado/refuerzo contra el paludismo. |
| US20100143302A1 (en) | 2006-03-16 | 2010-06-10 | Crucell Holland B.V. | Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof |
| WO2007110409A1 (en) * | 2006-03-27 | 2007-10-04 | Crucell Holland B.V. | Compositions comprising a recombinant adenovirus and an adjuvant |
| US20110091496A1 (en) * | 2008-01-19 | 2011-04-21 | Graham Barney S | Methods and compositions for the delivery of vaccines to disrupted epithelium |
| BR112013014712B1 (pt) | 2010-12-14 | 2021-03-02 | The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | primeiro e segundo vetores de adenovírus recombinantes |
-
2011
- 2011-12-14 BR BR112013014712-1A patent/BR112013014712B1/pt not_active IP Right Cessation
- 2011-12-14 US US13/994,532 patent/US9701718B2/en active Active
- 2011-12-14 ES ES11849865.8T patent/ES2676196T3/es active Active
- 2011-12-14 AU AU2011343798A patent/AU2011343798B2/en not_active Ceased
- 2011-12-14 JP JP2013544747A patent/JP6054876B2/ja active Active
- 2011-12-14 CA CA2821289A patent/CA2821289C/en active Active
- 2011-12-14 EA EA201390866A patent/EA029504B1/ru not_active IP Right Cessation
- 2011-12-14 CN CN201180067429.7A patent/CN103370411B/zh active Active
- 2011-12-14 KR KR1020137016833A patent/KR101879892B1/ko not_active Expired - Fee Related
- 2011-12-14 DK DK11849865.8T patent/DK2655604T3/en active
- 2011-12-14 EP EP11849865.8A patent/EP2655604B1/en active Active
- 2011-12-14 WO PCT/US2011/064944 patent/WO2012082918A1/en not_active Ceased
- 2011-12-14 PL PL11849865T patent/PL2655604T3/pl unknown
-
2013
- 2013-06-10 ZA ZA2013/04260A patent/ZA201304260B/en unknown
-
2016
- 2016-10-21 JP JP2016206679A patent/JP6268258B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201304260B (en) | 2021-05-26 |
| EP2655604A4 (en) | 2015-01-28 |
| JP6054876B2 (ja) | 2016-12-27 |
| EA201390866A1 (ru) | 2014-05-30 |
| US20140017278A1 (en) | 2014-01-16 |
| KR20140019304A (ko) | 2014-02-14 |
| CA2821289C (en) | 2019-05-21 |
| AU2011343798B2 (en) | 2016-07-14 |
| JP6268258B2 (ja) | 2018-01-24 |
| BR112013014712B1 (pt) | 2021-03-02 |
| EP2655604A1 (en) | 2013-10-30 |
| EP2655604B1 (en) | 2018-05-09 |
| WO2012082918A1 (en) | 2012-06-21 |
| JP2017048207A (ja) | 2017-03-09 |
| ES2676196T3 (es) | 2018-07-17 |
| CN103370411A (zh) | 2013-10-23 |
| CN103370411B (zh) | 2016-05-04 |
| CA2821289A1 (en) | 2012-06-21 |
| AU2011343798A1 (en) | 2013-07-11 |
| EA029504B1 (ru) | 2018-04-30 |
| DK2655604T3 (en) | 2018-08-06 |
| KR101879892B1 (ko) | 2018-08-17 |
| US9701718B2 (en) | 2017-07-11 |
| BR112013014712A2 (pt) | 2017-06-06 |
| JP2014503206A (ja) | 2014-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201304260B (en) | Adenovirus serotype 26 and serotype 35 filovirus vaccines | |
| IL249669B (en) | Converted 5-fluoro-h1-pyrazolopyridines and their use | |
| EP2560680A4 (en) | FILOVIRUS VACCINES ON CHIMPANZEE ADENOVINE VECTOR BASE | |
| PT2652025T (pt) | Composição secante e a sua utilização | |
| MY158037A (en) | Amphiphilic polysiloxane prepolymers and uses thereof | |
| IL215389A0 (en) | Pneumococcal vaccine and uses thereof | |
| PL2539326T3 (pl) | Połączone bis-arylem arylotriazolony i ich zastosowanie | |
| PL2605757T3 (pl) | Preparaty oparte na nalbufinie i ich zastosowania | |
| ZA201300930B (en) | St-246 liquid formulations and methods | |
| SG173751A1 (en) | Foxm1 peptides and vaccines containing the same | |
| HUE041512T2 (hu) | Új kombináció és alkalmazás | |
| AP2013006972A0 (en) | Adenovirus serotype 26 and serotype 35 filovirus vaccines | |
| ZA201303886B (en) | Tomm34 peptides and vaccines including the same | |
| IL214453A0 (en) | Vangli peptides and vaccines including the same | |
| IL221474A0 (en) | Hjurp peptides and vaccines including the same | |
| ZA201207342B (en) | Ect2 peptides and vaccines including the same | |
| IL220146A0 (en) | Tmem22 peptides and vaccines including the same | |
| IL215268A0 (en) | C6orf167 peptides and vaccines containing the same | |
| EP2536407A4 (en) | TAXAN-PRO-EMULSION FORMULATIONS AND METHOD FOR THEIR MANUFACTURE AND USE | |
| IL225552A0 (en) | wdhd1 peptides and vaccines containing them | |
| IL225553A0 (en) | 54orf18c peptides and vaccines containing them | |
| EP2657236A4 (en) | NEW 2-ALKYNYL-N9-PROPARGYLADENINE AND ITS MEDICAL USE | |
| GB201018131D0 (en) | 2 and 3 new poker |